Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Cash from Operations: 2010-2025

Historic Cash from Operations for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $20.5 million.

  • Arrowhead Pharmaceuticals' Cash from Operations rose 114.93% to $20.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $179.6 million, marking a year-over-year increase of 138.79%. This contributed to the annual value of $179.6 million for FY2025, which is 138.79% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Cash from Operations stood at $20.5 million for Q3 2025, which was up 113.24% from -$154.7 million recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Cash from Operations ranged from a high of $460.1 million in Q1 2025 and a low of -$154.7 million during Q2 2025.
  • Moreover, its 3-year median value for Cash from Operations was -$92.4 million (2024), whereas its average is -$32.9 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Cash from Operations surged by 1,056.58% in 2021, and later tumbled by 455.51% in 2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Cash from Operations (Quarterly) stood at -$61.3 million in 2021, then fell by 23.17% to -$75.5 million in 2022, then crashed by 56.05% to -$117.8 million in 2023, then dropped by 24.13% to -$146.3 million in 2024, then soared by 114.93% to $20.5 million in 2025.
  • Its Cash from Operations stands at $20.5 million for Q3 2025, versus -$154.7 million for Q2 2025 and $460.1 million for Q1 2025.